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Abstract.  
Background: Although in vivo studies have implicated endocannabinoids in metabolic 
dysfunction, little is known about direct, chronic activation of the endocannabinoid system 
(ECS) in human islets. Therefore, this study investigated the effects of prolonged exposure 
to cannabinoid agonists on human islet gene expression and function. 
Methods: Human islets were maintained for 2 and 5 days in the absence or presence of 
CB1r (ACEA) or CB2r (JWH015) agonists. Gene expression was quantified by RT-PCR, 
hormone levels by radioimmunoassay and apoptosis by caspase activities.  
Results: Human islets express an ECS, with mRNAs encoding the biosynthetic and 
degrading enzymes NAPE-PLD, FAAH and MAGL being considerably more abundant than 
DAGL, an enzyme involved in 2-AG synthesis, or CB1 and CB2 receptor mRNAs. 
Prolonged activation of CB1r and CB2r altered expression of mRNAs encoding ECS 
components, but did not have major effects on islet hormone secretion. JWH015 enhanced 
insulin and glucagon content at 2 days, but had no effect after 5 days. Treatment with ACEA 
or JWH015 for up to 5 days did not have marked effects on islet viability, as assessed by 
morphology and caspase activities. 
Conclusions: Maintenance of human islets for up to 5 days in the presence of CB1 and 
CB2 receptor agonists causes modifications in ECS element gene expression, but does not 
have any major impact on islet function or viability.  
General Significance: These data suggest that the metabolic dysfunction associated with 
over-activation of the ECS in obesity and diabetes in humans is unlikely to be secondary to 
impaired islet function. 
 
Keywords: human islets, endocannabinoid system, gene expression, insulin, glucagon, 
apoptosis. 
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Abbreviations 
ACEA: N-(2-Chloroethyl)-5Z,8Z,11Z,14Z-eiscosatetraenamide 
AEA: anandamide 
2-AG: 2-arachidonoyl glycerol 
CB1r: cannabinoid receptor type 1 
CB2r: cannabinoid receptor type 2 
DAGL: diacylglycerol lipase 
ECS: endocannabinoid system 
FAAH: fatty acid amide hydrolase 
JWH015: (2-methyl-1propyl-1H-indol-3-yl)-1-napthalenylmethanone 
MAGL: monoacylglycerol lipase 
NAPE-PLD: N-acyl-phosphatidyl ethanolamide-hydrolysing phospholipase D 
PPG: preproglucagon 
PPI: preproinsulin 
 
 
 
Highlights 
 Human islets express an endogenous cannabinoid system (ECS). 
 Prolonged activation of human islet CB1 and CB2 receptors modifies expression of ECS 
elements 
 This is not accompanied by marked changes in insulin and glucagon levels or islet 
viability. 
 Metabolic dysfunction following ECS activation is not due to impaired islet function or 
viability.  
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1. Introduction 
Islets of Langerhans have a limited capacity to adapt to different environmental 
challenges such as hyperglycaemia, hyperlipidaemia, pregnancy and obesity. When this 
narrow threshold is insufficient to compensate for alterations in metabolic state, inadequate 
-cell turnover and islet dysfunction may lead to the development of type 2 diabetes. In this 
context, accumulating evidence suggests that the endocannabinoid system (ECS) may be 
involved in the dysregulation of fuel homeostasis through the hypersecretion of the 
endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) from expanding 
adipocytes in obesity [1-8]. Sustained elevations in endocannabinoid levels in the circulation 
that occur following ECS over-activation in obese and diabetic patients are reported to have 
detrimental effects in peripheral organs, leading to impaired insulin sensitivity, glucose 
intolerance and dyslipidaemia [3, 4, 7, 9, 10]. In addition, central CB1 receptor activation by 
endocannabinoids has orexigenic effects [11-14], and chronic exposure to cannabinoids is 
reported to lead to changes in the expression of lipogenic genes and lipid content in 
hepatocytes [4, 15, 16], and to the induction of apoptosis in sebocytes [5]. 
Rodent and human islets express a local ECS consisting of the enzymes required for 
the synthesis (NAPE-PLD and DAGL) and degradation (FAAH and MAGL) of AEA and 2-
AG, and the endocannabinoids can activate the CB1 and CB2 cannabinoid receptors that 
are also expressed by islet cells [10, 17-35]. There is some controversy over whether acute 
activation of CB1 and CB2 receptors is coupled to stimulation [17, 19, 23-27, 29-31, 33, 34], 
or inhibition [10, 18, 22, 28, 32] of insulin secretion from rodent islets. However, our earlier 
studies in isolated human islets indicate that CB1 and CB2 receptor agonists can stimulate 
insulin secretion [17, 30], suggesting that cannabinoids may have beneficial effects in human 
-cells. Most studies investigating the effects of cannabinoid agonists and antagonists on 
islet function in vitro have focused on acute signalling [10, 18, 19, 22, 23, 25-34], but 2-AG 
and AEA levels are chronically elevated in the pancreas under conditions of diet-induced 
obesity [6, 25], and these endocannabinoids are also increased in human islets in response 
to high glucose concentrations [3, 10]. Excess endocannabinoid production by the local islet 
ECS in obesity and diabetes could therefore have a chronic impact on islet function [35].  
We have previously evaluated the long term effects of mouse islet CB1r or CB2r 
over-activation on ECS gene expression, on insulin and glucagon secretion and on islet 
viability, and found that there were no major functional effects [24]. However, similar studies 
on the effects of chronic exposure of human islets to cannabinoids have not been carried out 
although cannabinoids have been implicated in mouse -cell death [22]. Therefore, the aim 
of the current study was to identify whether isolated human islets maintained chronically with 
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cannabinoid agonists show modifications in expression of genes coding for elements of the 
ECS, and/or alterations in islet secretory function and viability. 
 
2. Materials and Methods 
2.1 Materials. 
DMEM (5.5mM glucose), penicillin/streptomycin, L-glutamine, collagenase (Type XI), 
and PCR primers for human CB1r, CB2r, MAGL, NAPE-PLD, FAAH, DAGL and 18s rRNA 
were purchased from Sigma Aldrich (Dorset, UK). Primers for human preproinsulin and 
preproglucagon, RNeasy mini kits, and QuantiFast SYBR Green PCR Kit, were obtained 
from Qiagen (West Sussex, UK). Real-time PCR master mix and plates were purchased 
from Roche Diagnostics Ltd. (West Sussex, UK). N-(2-chloroethyl)-5Z,8Z,11Z,14Z-
eiscosatetraenamide (ACEA) and (2-methyl-1propyl-1H-indol-3-yl)-1-napthalenylmethanone 
(JWH015) were from Tocris Biosciences (Bristol, UK). Fetal bovine serum and reverse 
transcription reagents were purchased from Invitrogen (Paisley, UK), and Caspase-3/7-Glo 
apoptosis kits were obtained from Promega UK (Southampton, UK). 
 
2.2 Human islet exposure to cannabinoids. 
Human islets were isolated and purified from non-diabetic, heart-beating donors (with 
ethical permission) by the King’s College Islet Transplantation Unit, as previously reported 
[36]. Human islets from eight separate donors with the following characteristics were used in 
this study: 5 male, 3 female; age 454.2; BMI 271.0. Hand-picked, size-matched islets 
were maintained in culture with DMEM containing 5.5mM glucose, 10% FBS, 2mM L-
glutamine, and 100 units/ml penicillin/100g/ml streptomycin, for 2 or 5 days in the presence 
or absence of either 100nM of the CB1r-selective agonist ACEA, or 100nM of the CB2r-
selective agonist JWH015. Control groups of islets were incubated in the presence of 
0.001% DMSO, the vehicle used for preparation of ACEA and JWH015. Culture media 
replacement and microscopic observation of the islets was performed daily.  
 
2.3 Polymerase chain reaction (PCR).  
Total RNA was isolated using RNeasy mini kits from groups of 150-200 human islets 
previously treated for 2 or 5 days in the absence or presence of ACEA or JWH015 except for 
quantification of mRNAs encoding ECS elements, where four groups of 150-200 human 
islets were incubated overnight, without treatment, immediately after provision by the King’s 
College Islet Transplantation Unit. RNA samples were adjusted to obtain 20-50ng/l of 
cDNA by reverse transcription reactions, as previously reported [24]. Real-time SYBR Green 
PCR amplifications were performed with a LightCycler 480 96 well-plate system, using the 
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primers and conditions described in Table 1. Relative expression of mRNAs was determined 
after normalisation against 18s rRNA as an internal reference gene, and calculated by the 2-
Ct method [37].  
 
2.4 Insulin and glucagon secretion. 
Human islets that had been maintained in culture for 2 or 5 days in the absence or 
presence of 100nM ACEA or 100nM JWH015 were washed then pre-incubated for one hour 
at 37°C in 400l of physiological buffer [38] containing 2mM glucose. For measurements of 
insulin and glucagon secretion groups of 5 and 10 islets respectively were transferred to 
Eppendorf tubes and incubated for one hour at 37°C in 500l of buffer supplemented with 
16mM glucose or 10mM arginine. Insulin and glucagon secreted from the islets in these 
static incubation experiments was quantified by radioimmunoassay [17,39].  
 
2.5 Insulin and glucagon content.  
Acidified ethanol (100l) was added to four groups of 10 human islets that had been 
exposed for 2 or 5 days to DMEM (5.5mM glucose) alone or with DMEM supplemented with 
100nM of either ACEA or JWH015. The islet samples were sonicated and stored at -20°C 
until radioimmunoassays were performed to measure insulin and glucagon contents. 
 
2.6 Caspase-3/7 activities.  
The extent of apoptosis of human islets previously maintained for 2 or 5 days in the 
absence or presence of cannabinoid agonists was determined by detection of caspase-3/7 
activities with a luminometer following cleavage of a proluminescent substrate (Z-DEVD-
aminoluciferin), as previously reported [40]. Apoptosis was induced in these experiments by 
exposing five islets from each group to a cytokine cocktail (0.5U/l IL-1, 5U/l TNF, and 
5U/l IFN) for the final 20 hours of incubation. 
 
2.7 Statistical analysis. 
Data are expressed as means ± SEM of 3 or 4 individual experiments. One-way and 
two-way ANOVA with Bonferroni’s test were used for analyses and differences between 
treatments were considered statistically significant at p<0.05.  
 
3. Results  
3.1 Relative mRNA expression of the endocannabinoid signalling elements in human islets. 
Quantitative RT-PCR using human islet cDNAs indicated that the mRNA encoding 
FAAH, an enzyme responsible for degradation of the endocannabinoid AEA, was the most 
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abundant component of the endocannabinoid system in human islets. It was expressed at 
levels similar to the mRNA coding for NAPE-PLD, which catalyses biosynthesis of AEA from 
the membrane phospholipid N-acylphosphatidylethanolamine, and both mRNAs were of 
similar abundance to preproglucagon mRNA (Figure 1). The mRNAs encoding the enzymes 
that regulate the synthesis (DAGL) and degradation (MAGL) of the other major 
endocannabinoid, 2-AG, were also detected in human islets but these, in particular DAGL, 
showed lower levels of expression than NAPE-PLD and FAAH mRNAs (Figure 1). Figure 1 
also indicates that CB1 and CB2 receptor mRNAs were detectable in human islets, but their 
expression levels were only approximately 0.1% of those of preproinsulin mRNA, which 
encodes the major islet hormone.  
 
3.2 Effects of prolonged exposure to ACEA and JWH015 on ECS element gene expression 
in human islets. 
Quantitative RT-PCR demonstrated that human islets exposed to a CB1r (100nM 
ACEA) or CB2r (100nM JWH015) agonist for 2 or 5 days affected expression of ECS 
elements. Thus, as can be seen from Figure 2A, stimulation of CB1r with ACEA (grey bars) 
induced significant decreases in NAPE-PLD, FAAH and MAGL mRNA levels at 2 days. 
While exposure of islets to JWH015 for 2 days (black bars) also significantly decreased 
NAPE-PLD mRNA it did not affect FAAH or MAGL expression, but it did induce significant 
up-regulation of mRNAs encoding CB1r and CB2r. Exposure of islets to ACEA for 5 days 
induced a 50% increase in CB1r mRNA levels and a significant reduction in DAGL mRNA 
expression (Figure 2B), while 100nM JWH015 caused at least 50% reductions in mRNAs 
encoding CB1r, FAAH and MAGL after 5days. These gene expression studies indicate that 
relatively short-term activation of CB1r by ACEA caused down-regulation of mRNAs 
encoding enzymes involved in endocannabinoid synthesis and degradation in human islets 
within 2 days, while chronic activation of CB2 receptors over 5 days decreased mRNAs 
encoding cannabinoid degradation.  
3.3 Effects of prolonged cannabinoid receptor activation on insulin and glucagon secretion 
from human islets 
Static incubation secretion experiments were performed to evaluate whether chronic 
exposure to the cannabinoid agonists affected acute glucose-stimulated insulin secretion 
(Figure 3A and 3C) or acute arginine-induced glucagon secretion (Figure 3B and 3D) from 
human islets previously maintained in culture in the absence or presence of 100nM ACEA or 
JWH015 for 2 (upper panels) or 5 days (lower panels). 
Islets that had been maintained in culture for 2 days and 5 days showed significant 
elevations in insulin secretion in response to 16mM glucose (Figure 3A and 3C, control), 
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although basal and glucose-stimulated insulin secretion were significantly reduced after 5 
days in culture, compared to culture for 2 days. Basal insulin secretion at 3mM glucose was 
significantly increased in human islets after incubation for 2 days with 100nM ACEA, but the 
magnitude of insulin secretion at 16mM glucose was not affected by 48 hour pre-exposure to 
ACEA (Figure 3A). Islets that had been treated with ACEA for 5 days showed a reduced 
secretory response to 16mM glucose, but there was still a significant elevation in insulin 
release over the low basal insulin output (Figure 3C). Treatment of human islets with 100nM 
JWH015 for 2 days and 5 days had no significant effect on basal or glucose-stimulated 
insulin secretion (Figure 3A and 3C).  
Islets responded to acute exposure to 10mM arginine after 2 and 5 days in culture 
with significant elevations in glucagon secretion (Figure 3B and 3D, control), although the 
extent of glucagon release was significantly reduced after 5 days. Pre-exposure of human 
islets to 100nM ACEA for 2 days significantly elevated basal glucagon secretion without 
modifying the amplitude of the glucagon secretory response to 10mM arginine (Figure 3B), 
while islets incubated with ACEA for 5 days did not show any alterations in basal or arginine-
stimulated glucagon output (Figure 3D). Islets that had been exposed to JWH015 did not 
show a significant glucagon secretory response to 10mM arginine (Figure 3B), but they 
responded appropriately to arginine after they had been maintained in the presence of 
JWH015 for 5 days (Figure 3D).  
 
3.4 Effects of chronic exposure to cannabinoid receptors agonists on insulin and glucagon 
content in human islets. 
Since prolonged culture of human islets resulted in changes in insulin and glucagon 
secretion, as shown in Figure 3, further experiments were carried out to quantify hormone 
content after 2 days and 5 days culture in the absence and presence of ACEA and JWH015. 
It can be seen from Figure 4C (white bars) that maintenance of human islets in culture for 5 
days resulted in significant reduction in insulin content compared to islets after 2 days in 
culture (Figure 4A), but there was no significant change in glucagon content of the islets 
under the same conditions (Figure 4B and 4D, white bars). Exposure of human islets to the 
CB1r agonist ACEA for 2 and 5 days had no effect on insulin content (Figure 4A and 4C, 
grey bars). However, ACEA induced a significant increase in glucagon content after 2 days 
(Figure 4B, grey bars), and this could be responsible for the elevated basal glucagon 
secretory response seen after maintenance of islets in the presence of 100nM ACEA for 2 
days (Figure 3B). The CB2r agonist JWH015 caused a marked increase in insulin content at 
2 days (Figure 4A, black bars). This increase was not sustained after 5 days of treatment 
with JWH015, and islet insulin levels under this condition were not significantly different from 
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the reduced content seen in the control islets. JWH015 also increased islet glucagon content 
after 2 days, but not at 5 days (Figure 4B, black bars). 
 
3.5 Effects of chronic exposure to cannabinoid receptor agonists on human islet morphology 
and apoptosis. 
The photomicrographs of human islets (Figure 5) indicate that maintenance for 2 
days (upper panels) or 5 days (lower panels) in the absence (left) or presence of 100nM 
ACEA (middle) or JWH015 (right) did not cause any major deleterious effects on integrity, 
although after 5 days in culture all islets were generally less compact, with the loss of some 
cells. This was associated with increased basal apoptosis after 5 days compared to that 
seen at 2 days (Figure 6A control, white bars versus Figure 6B). Evaluation of the effects of 
chronic exposure to cannabinoid agonists on human islet cell caspase 3/7 activities was 
carried out in the absence and presence of mixed cytokines (black bars) and these studies 
indicated that pre-exposure to ACEA and JWH015 for 2 (Figure 6A) or 5 days (Figure 6B) 
had no effects on human islet cell apoptosis.  
 
4. Discussion 
We, and others, have previously identified components of a local ECS in human 
islets by PCR and immunohistochemistry [10, 17, 20, 21, 30], but the relative expression of 
these elements has not been fully investigated. Our observations indicate a relatively high 
mRNA expression of FAAH, NAPE-PLD and MAGL in human islets, while DAGL and both 
cannabinoid receptors show lower expression levels. The high levels of FAAH mRNA that 
we detected in human islets is consistent with our earlier observations that this is the most 
abundant ECS mRNA in mouse islets [24], as are our observations of low levels of CB1r, 
CB2r and DAGL. It has previously been reported that CB1 expression is considerably 
higher than CB2 in human islets [20], but this differential expression of the cannabinoid 
receptors was not confirmed in the current study. We did find here that human islets express 
substantially more MAGL mRNA than mouse islets do [17, 24], suggesting that 2-AG levels 
are tightly controlled in human islets through MAGL-dependent degradation. Since whole 
islets were used for mRNA purification in these studies and our earlier work with mouse 
islets [24], it was not possible to determine the distribution and specific expression of the 
ECS elements in each islet cell type, but immunofluorescence staining of human pancreas 
has indicated the presence of MAGL, DAGL, NAPE-PLD and FAAH in -cells [10]. It is 
therefore likely that the endogenous production, accumulation and degradation of 
endocannabinoids is important in the modulation of islet functions.  
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Previous studies have demonstrated that expression of ECS components is a 
dynamic process that is modified in response to high fat diet, and high glucose 
concentrations are reported to increase AEA and 2-AG synthesis in rodent and human islets 
[10, 20]. In the current study the effects of 100nM of CB1r (ACEA) and CB2r (JWH015) 
agonists were investigated, to provide a direct comparison with an earlier study in which we 
had investigated the effects of chronic activation of cannabinoid receptors in mouse islets 
[24]. The changes that we observed in mRNA levels in isolated human islets of the enzymes 
involved in the synthesis and degradation of endocannabinoids suggest a negative feedback 
mechanism in the presence of exogenous agonists, most likely to limit endogenous 
endocannabinoid levels to minimise over-stimulation of the CB1 and CB2 receptors. 
However, it is interesting that while chronic activation of human islet cannabinoid receptors 
led to depletion of mRNAs responsible for regulation of endocannabinoid levels there was a 
simultaneous increase in the mRNAs encoding CB1r and CB2r, which may have been a 
mechanism for sustained responses to these ligands. Generation of AEA and 2-AG in the 
human islets following exposure to ACEA and JWH015 was not quantified in the current 
study, but it is possible that the up-regulation of CB1r as well as CB2r mRNA following 
exposure to JWH015 for 2 days was a consequence of altered synthesis of the CB1r ligand 
AEA by the islets. The role played by endogenous human islet endocannabinoids in the 
patterns of ECS gene expression observed here will be the subject of future work.  
 These changes in the ECS mRNAs in human islets in vitro support a model of 
dynamic regulation of islet endocannabinoid content to maintain the “on-demand” responses 
of islets to physiological and pathological stimuli [3, 6, 19, 24, 26, 31, 32]. However, the 
current study does not provide direct information that islets in situ would necessarily respond 
in the same manner as islets in vitro. Moreover, the use of whole islets, while providing an 
appropriate physiological model, does not allow identification of the cells in which the 
alterations in ECS mRNAs occurs.  
Although exposure of human islets to ACEA and JWH015 for 2 days increased 
insulin and glucagon content, there were no marked effects on acute secretion of these 
hormones, suggesting that islet stores of insulin and glucagon were enhanced, rather than - 
or -cell secretory capacity. Overall, maintenance of human islets with the cannabinoid 
receptor agonists was without deleterious effects, either on the capacity of islets to secrete 
insulin and glucagon in response to glucose and arginine respectively, or in terms of islet cell 
viability. Our observations that apoptosis was not enhanced by exposure of islets to CB1r or 
CB2r agonists is in contrast to observations that acute and chronic exposure to cannabinoids 
induces apoptosis in a number of cell types [5, 41-43], including islet -cells [22]. However, 
there is also evidence supporting a protective role of 2-AG and AEA in cell survival [44-47], 
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and we have previously reported that pre-exposure of mouse islets to 100nM ACEA or 
JWH015 for 7 days protects against cytokine-induced apoptosis [24]. A similar protective 
effect was not observed in the current studies, which may reflect the 5 day time-course of 
exposure here and 7 days with mouse islets, or it may indicate species-dependent 
differences in apoptotic signalling downstream of cannabinoid receptor activation in mouse 
and human islets. Nonetheless, our data clearly demonstrate that chronic treatment of 
human islets with 100nM ACEA or JWH015 does not induce apoptosis. This apparent 
discrepancy with an earlier study in islets [22] may be due to the use in that study of 25M 2-
AG and AEA to maximally reduce islet cell viability over 48 hours, a concentration that is 
several orders of magnitude higher than detected in diabetes [3], and considerably higher 
than those used in the current study.  
 
5. Conclusion 
 In conclusion, we report that prolonged maintenance of isolated human islets in the 
presence of cannabinoid CB1 and CB2 receptor agonists modulates the gene expression of 
ECS components and promotes short-term increases in islet insulin and glucagon content, 
but does not exert deleterious effects on islet viability or function. Our results suggest that 
over-activation of islet endocannabinoid receptors induces an adaptation process through 
down-regulation of endogenous islet cannabinoid levels, but the maintenance of islet viability 
and function suggests that islet cell death and dysfunction do not play a role in the metabolic 
defects arising from over-activation of the ECS in obesity and diabetes. Thus, these data are 
consistent with the impairments in glucose homeostasis observed following increased 
production of endocannabinoids being a consequence of insulin resistance rather than -cell 
dysfunction or -cell hypersecretion. 
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Table 1. Primer sequences and annealing temperatures used in real-time PCR. 
 
Gene name for Homo sapiens 
 
Primer sequences 
Annealing 
temp. 
Cannabinoid receptor 1 (CB1r) 
F 5'-CACCTTCCGCACCATCACCAC-3' 
R 5'-GTCTCCCGCAGTCATCTTCTCTTG-3' 
60 °C 
Cannabinoid receptor 2 (CB2r) 
F 5'-CATGGAGGAATGCTGGGTGAC-3' 
R 5'-GAGGAAGGCGATGAACAGGAG-3' 
62 °C 
Diacylglycerol lipase alpha 
(DAGL) 
F 5'-AGAATGTCACCCTCGGAATGG-3' 
R 5'-GTGGCTCTCAGCTTGACAAAGG-3' 
62 °C 
Monoacylglycerol lipase (MAGL) 
F 5'-CAAGGCCCTCATCTTTGTGT-3' 
R 5'-ACGTGGAAGTCAGACACTAC-3' 
60 °C 
Fatty acid amide hydrolase (FAAH) 
F 5'-CCCAGATGGAACATTACAGG-3'    
R 5’-CAGGATGACTGGTTTTCAGG-3’ 
60 °C 
N-acyl phosphatidylethanolamine 
phospholipase D (NAPE-PLD) 
F 5’-CACGGTAATGGTGGAAATGG-3’ 
R 5’-GTCCAGATGGTCATAGTGGTTG-3’ 
62 °C 
18s rRNA 
F 5’-GGGAGCCTGAGAAACGG-3’ 
R 5’-GGGTCGGGAGTGGGTAATTT-3’ 
60 °C 
Preproinsulin Qiagen Quantitect primer 60 °C 
Preproglucagon Qiagen Quantitect primer 60 °C 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
Figure Legends 
 
Figure 1. Groups of 150-200 human islets were incubated overnight after isolation under 
standard culture conditions and qPCR was used to quantify relative expression of human 
islet mRNAs encoding preproinsulin (PPI), preproglucagon (PPG), and the enzymes and 
receptors of the endocannabinoid system. Data are expressed as relative percentage with 
respect to PPI mRNA levels, obtained from real-time PCR amplification values, normalised 
to 18s rRNA as an internal reference (means+SEM, n=4). 
 
Figure 2. Quantification of mRNAs encoding elements of the ECS in human islets after 
maintenance for 2 (A) and 5 days (B) in DMEM (5.5mM glucose) alone (open bars) or 
supplemented with 100nM ACEA (grey bars) or 100nM JWH015 (black bars). Data are 
expressed relative to the levels present in control islets in the absence of cannabinoid 
receptor agonists and normalised to 18s rRNA levels in the same samples; means+SEM, 
n=4 experiments. Data were analysed by one-way ANOVA; *p<0.05, **p<0.01 compared to 
the appropriate control.  
 
Figure 3. Acute, one hour insulin (panels A and C) and glucagon (panels B and D) secretion 
from human islets after maintenance for 2 (upper panels) or 5 (lower panels) days in DMEM 
containing 5.5mM glucose alone (control), or supplemented with 100nM ACEA or 100nM 
JWH015. Basal levels of insulin and glucagon secretion at 3mM glucose are shown by the 
open bars and the black bars show insulin secretion at 16mM glucose (panels A and C) and 
glucagon secretion at 10mM arginine panels B and D); means+SEM, n=4 experiments. Data 
were analysed by two-way ANOVA; *p<0.05, **p<0.01 versus the appropriate basal 
secretion, #p<0.05 versus the appropriate control. 
Figure 4. Insulin (panels A and C) and glucagon (panels B and D) hormone contents of 
human islets maintained for 2 (upper panels) or 5 (lower panels) days in the absence of 
cannabinoid receptor agonists (open bars) or with 100nM ACEA (grey bars) or 100nM 
JWH015 (black bars). Data are expressed as ng/islet (means+SEM, n=4). Data were 
analysed by one-way ANOVA; *p<0.05, **p<0.01 versus the appropriate control.  
 
Figure 5. Micrographs of human islets maintained in culture for 2 (upper panels) or 5 (lower 
panels) days in DMEM containing 5.5mM glucose (left) or supplemented with 100nM ACEA 
(middle) or 100nM JWH015 (right). Micrographs are representative of 3 experiments using 
islets obtained from three different donors. 
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Figure 6. Caspase-3/7 activities in human islets after maintenance for 2 (panel A) or 5 
(panel B) days in DMEM containing 5.5mM glucose alone (control) or supplemented with 
100nM ACEA or 100nM JWH015. Apoptosis was induced by adding a cytokine cocktail 
(0.5U/ml IL1, 5U/ml TNF, and 5U/ml IFN) for the final 20 hours of incubation, shown by 
the black bars. Data are expressed in luminescence units (means+SEM, n=6 for panel A, 
n=4 for panel B). Data were analysed by two-way ANOVA; *p<0.05 with respect to basal 
apoptosis in the absence of cytokines. 
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